Valuation: Norda ASA

Market Cap 513M 53.34M 46.91M 43.58M 40.08M 75.16M 5.17B 76.51M 521M 203M 2.52B 200M 196M 8.74B P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 264M 27.48M 24.16M 22.45M 20.65M 38.72M 2.66B 39.41M 268M 105M 1.3B 103M 101M 4.5B EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day+1.53%
3 months+1.53%
6 months+6.67%
Current year-13.60%
Current year 81
Extreme 81
86.4
1 year 80.1
Extreme 80.1
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 2013-04-07
Director TitleAgeSince
Chairman 54 2014-01-30
Director/Board Member 68 2013-06-19
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.53%-.--%+8.00%+110.73% 46.19M
+1.08%-6.74%-2.31%+10.45% 46.06B
+4.03%+5.31%+402.77%+627.41% 38.91B
+14.93%+2.79%+10.66%+67.11% 35.57B
+5.94%-1.56%+6.67%-9.18% 33.13B
+1.23%-1.99%-0.05%+30.76% 26.42B
+4.98%-2.77% - - 16.61B
+17.67%+12.60%+38.47%+145.28% 15.08B
-6.32%-4.59%+4.36%+8.22% 14.08B
-6.72%+0.14%+1.39%-29.84% 12.81B
Average +2.36%-1.76%+52.22%+106.77% 23.87B
Weighted average by Cap. +2.40%-2.47%+75.75%+133.81%

Financials

2023 2024
Net sales 86.92M 9.03M 7.95M 7.38M 6.79M 12.73M 875M 12.96M 88.27M 34.43M 427M 33.92M 33.18M 1.48B 372M 38.65M 33.99M 31.58M 29.04M 54.47M 3.74B 55.44M 378M 147M 1.83B 145M 142M 6.33B
Net income 31.17M 3.24M 2.85M 2.65M 2.43M 4.57M 314M 4.65M 31.66M 12.35M 153M 12.16M 11.9M 531M 126M 13.09M 11.51M 10.7M 9.84M 18.45M 1.27B 18.78M 128M 49.89M 618M 49.14M 48.08M 2.15B
Net Debt -311M -32.35M -28.45M -26.43M -24.31M -45.59M -3.13B -46.4M -316M -123M -1.53B -121M -119M -5.3B -249M -25.86M -22.74M -21.13M -19.43M -36.44M -2.5B -37.1M -253M -98.55M -1.22B -97.09M -94.99M -4.24B
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
  1. Stock Market
  2. Stocks
  3. NORD Stock